Literature DB >> 12928104

Targeted prefrontal cortical activation with bifrontal ECT.

Hal Blumenfeld1, Kelly A McNally, Robert B Ostroff, I George Zubal.   

Abstract

The anatomical brain regions involved in the therapeutic and adverse actions of electroconvulsive therapy (ECT) are unknown. Previous studies suggest that bifrontal vs. bitemporal ECT differ in therapeutic efficacy and cognitive side effects. We therefore performed cerebral blood flow (CBF) imaging during bitemporal vs. bifrontal ECT-induced seizures to identify regions crucial for the differences between these treatments. Patients with major depression, undergoing bitemporal or bifrontal ECT, were studied. Ictal-interictal SPECT images were analyzed with statistical parametric mapping for bitemporal (n=11 image pairs in 8 patients) and bifrontal (n=4 image pairs in 2 patients) ECT-induced seizures to identify regions of ictal CBF changes. Bifrontal ECT was found to cause increases in CBF in prefrontal and anterior cingulate regions. Bitemporal ECT, however, caused CBF increases in the lateral frontal cortex and in the anterior temporal lobes. In bifrontal ECT, a greater increase in prefrontal activation, while sparing the temporal lobes, may result in a better therapeutic response and fewer adverse effects on memory than bitemporal ECT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928104     DOI: 10.1016/s0925-4927(03)00073-8

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  14 in total

Review 1.  Consciousness and epilepsy: why are patients with absence seizures absent?

Authors:  Hal Blumenfeld
Journal:  Prog Brain Res       Date:  2005       Impact factor: 2.453

Review 2.  Epilepsy and the consciousness system: transient vegetative state?

Authors:  Hal Blumenfeld
Journal:  Neurol Clin       Date:  2011-11       Impact factor: 3.806

3.  Impaired consciousness in epilepsy.

Authors:  Hal Blumenfeld
Journal:  Lancet Neurol       Date:  2012-09       Impact factor: 44.182

4.  Electric field strength and focality in electroconvulsive therapy and magnetic seizure therapy: a finite element simulation study.

Authors:  Zhi-De Deng; Sarah H Lisanby; Angel V Peterchev
Journal:  J Neural Eng       Date:  2011-01-19       Impact factor: 5.379

Review 5.  Brain mechanisms of altered conscious states during epileptic seizures.

Authors:  Andrea Eugenio Cavanna; Francesco Monaco
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

6.  Controlling stimulation strength and focality in electroconvulsive therapy via current amplitude and electrode size and spacing: comparison with magnetic seizure therapy.

Authors:  Zhi-De Deng; Sarah H Lisanby; Angel V Peterchev
Journal:  J ECT       Date:  2013-12       Impact factor: 3.635

7.  Focal BOLD fMRI changes in bicuculline-induced tonic-clonic seizures in the rat.

Authors:  Matthew N DeSalvo; Ulrich Schridde; Asht M Mishra; Joshua E Motelow; Michael J Purcaro; Nathan Danielson; Xiaoxiao Bai; Fahmeed Hyder; Hal Blumenfeld
Journal:  Neuroimage       Date:  2010-01-14       Impact factor: 6.556

8.  Auditory processing of sine tones before, during and after ECT in depressed patients by fMRI.

Authors:  Martin Christ; Nikolaus Michael; Hermina Hihn; Anne Schüttke; Carsten Konrad; Bernhard T Baune; Andreas Jansen; Bettina Pfleiderer
Journal:  J Neural Transm (Vienna)       Date:  2008-03-04       Impact factor: 3.575

9.  Clinical use of ictal SPECT in secondarily generalized tonic-clonic seizures.

Authors:  G I Varghese; M J Purcaro; J E Motelow; M Enev; K A McNally; A R Levin; L J Hirsch; R Tikofsky; A L Paige; I G Zubal; S S Spencer; H Blumenfeld
Journal:  Brain       Date:  2009-04-01       Impact factor: 13.501

10.  Cortical and subcortical networks in human secondarily generalized tonic-clonic seizures.

Authors:  H Blumenfeld; G I Varghese; M J Purcaro; J E Motelow; M Enev; K A McNally; A R Levin; L J Hirsch; R Tikofsky; I G Zubal; A L Paige; S S Spencer
Journal:  Brain       Date:  2009-04-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.